Abstract: The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of psoriasis or cancer or precancerous conditions.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: Methods of inactivating contaminants of a biological matrix are disclosed. The methods include the steps of: (a) contacting a biological matrix with an inactivating agent including an aziridino moiety, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a solid support including at least 1 quenching moiety attached to the solid support through covalent bonds, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the solid support and the unreacted agent from the biological matrix, where the unreacted agent is attached to the solid support through covalent bonds.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: 1

Abstract: This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: 1

Abstract: Methods and compositions for the inactivation and removal of contaminants of a biological composition are disclosed. The methods include the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a lipophilic quenching agent including at least one quenching moiety attached to a lipophilic moiety, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the lipophilic quenching agent and the quenched inactivating agent from the biological composition.

Abstract: The invention features a method of inactivating a contaminant, such as a virus, of a biological composition. The method includes the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety or a haloderivative salt thereof, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a composition which includes one quenching moiety under conditions and for a time sufficient to allow the inactivating agent to bond covalently to the quenching moiety; and (c) separating the quenching moiety and the quenched inactivating agent from the biological composition.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.

Abstract: The present invention provides methods for treating rhinoviral infections in a subject in need of such treatment, by the administration of 2′-5′ oligoadenylates or the analogs thereof. Pharmaceutical formulations comprising 2′-5′ oligoadenylates and analogs thereof are also provided.

Abstract: Methods of inactivating contaminants of a biological matrix are disclosed. The methods include the steps of: (a) contacting a biological matrix with an inactivating agent including an aziridino moiety, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a solid support including at least 1 quenching moiety attached to the solid support through covalent bonds, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the solid support and the unreacted agent from the biological matrix, where the unreacted agent is attached to the solid support through covalent bonds.

Abstract: The invention features a method of inactivating a contaminant, such as a virus, of a biological composition. The method includes the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety or a haloderivative salt thereof, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a composition which includes one quenching moiety under conditions and for a time sufficient to allow the inactivating agent to bond covalently to the quenching moiety; and (c) separating the quenching moiety and the quenched inactivating agent from the biological composition.

Abstract: 2′,5′-oligoadenylate-2′,3′-cyclophosphates having the chemical structure of Formula I: 1

Abstract: Methods of inactivating contaminants of a biological matrix are disclosed. The methods include the steps of: (a) contacting a biological matrix with an inactivating agent including an aziridino moiety, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a solid support including at least 1 quenching moiety attached to the solid support through covalent bonds, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the solid support and the unreacted agent from the biological matrix, where the unreacted agent is attached to the solid support through covalent bonds.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: The invention features a method for inactivating microorganisms such as viruses and bacteria in a preparation of purified mammalian cells which, when mature, lack a nucleus (e.g., red blood cells or platelets). The method includes contacting the preparation with ethyleneimine dimer under viral inactivating conditions for a period of time sufficient to inactivate at least some of the microorganismsin the preparation. Also disclosed is a method for removing ethyleneimine dimer from a treated biological composition following inactivation, without the addition of any quenching agent.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.

Abstract: Methods and compositions for the inactivation and removal of contaminants of a biological composition are disclosed. The methods include the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a lipophilic quenching agent including at least one quenching moiety attached to a lipophilic moiety, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the lipophilic quenching agent and the quenched inactivating agent from the biological composition.

Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: ##STR1## where each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 cannot all be H; R.sub.5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 1 and 10, inclusive are disclosed.

Abstract: The present invention provides methods for treating herpes infections in a subject in need of such treatment, by the administration of 2'-5' oligoadenylate-2',3'-cyclophosphate compounds. Pharmaceutical formulations comprising 2'-5' oligoadenylate-2',3'-cyclophosphate and compounds thereof are also provided.